BioMarin’s Amicus Deal & Voxzogo Surge Drive Strong Growth and Cash‑Flow
BioMarin’s Amicus acquisition and Voxzogo’s sales surge give the company a cash‑flow base and high‑growth engine for rare‑disease therapy.
4 minutes to read
BioMarin Pharmaceutical Inc
BioMarin’s $4.8 B Deal for Amicus Sparks 30% Share Rally & 164% Option Surge
BioMarin’s $4.8 B acquisition of Amicus Therapeutics expands its lysosomal storage disease portfolio, boosting stock, options, and investor optimism.
3 minutes to read
BioMarin’s PALYNZIQ Achieves Landmark Success in Phase-3 Trial for Adolescents with PKU
BioMarin Pharmaceutical Inc. announced that its enzyme-replacement therapy, PALYNZIQ, achieved a 49.7% reduction in mean blood phenylalanine levels among adolescents with phenylketonuria in a Phase-3 study, marking a significant milestone for the co…
3 minutes to read
BioMarin Surpasses Q2 2025 Expectations with Strong Financial Results and Strategic Growth
BioMarin Pharmaceutical Inc. exceeded market expectations in Q2 2025, reporting a revenue of $825 million and raising its full-year guidance to $3.125 billion.
3 minutes to read
BioMarin Acquires Inozyme Pharma to Expand Enzyme Therapy Portfolio Amid Market Volatility
BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma, expanding its enzyme therapy portfolio and positioning itself as a frontrunner in addressing rare diseases.
3 minutes to read